An Early Phase 1 interventional study of Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets in Type 1 Diabetes Mellitus, sponsored by Assiut University. Not yet recruiting. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-04-12.
Sponsored by Assiut University · Early Phase 1, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Diabetes Mellitus, Type 1 by Assiut University — 7 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Assiut University.
Among the 11 studies in Diabetes Mellitus, Type 1 by Assiut University, this one is one of 2 that started in 2024, is the only one in phase 1, and was the 6th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →7 of the 11 studies in Diabetes Mellitus, Type 1 by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University · Sites in Egypt
Ages up to 18 · Healthy volunteers
Assiut University
Ages 18–80
Assiut University
Ages 1–18 · Healthy volunteers
Assiut University
Ages 1–18
Assiut University
Ages 8–15
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 2 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 100 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 100 across the 1 interventional studies, 115 across the 10 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Diabetes Mellitus, Type 1 by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07845175Assiut UniversityGastrointestinal Symptoms in Children With Type 1 Diabetes | 2027-09-26 |
| NCT07476248Assiut UniversityThe Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to High-density Lipoprotein Cholesterol (HDL-C) Ratio (NHHR) and Its Association With Occurrence of Diabetic Nephropathy in Patients With Diabetes Mellitus | 2027-10-01 |
| NCT07807553Assiut UniversityLiver Function Test Abnormalities in Pediatric Type 1 Diabetes | 2027-10-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies in Diabetes Mellitus, Type 1 by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Determine the effect of Coenzyme Q10 on random blood sugar and glycosylated haemoglobin
Type 1 diabetes mellitus is an autoimmune disease that leads to destruction of insulin producing pancreatic Beta cells.
Individuals with type 1 diabetes requires life long insulin replacement with multiple daily insulin injection. daily,insulin pump therapy or the use of an automated insulin delivery system.
without insulin ,diabetic ketoacidosis develops and is life threatening.
In addition to insulin Therapy ,glucose monitoring with a continuous glucose monitor and a blood glucose monitor if continuous glucose monitor is unavailable is recommended .
Coenzyme Q10 supplementation has beneficial effects on glycemic control especially in diabetes , and 100-200 mg per day of Co Q10 could achieve the greatest benefit which could provide a basis for the dietary guidelines of Co Q10 in patients with glycemic disorders .
Co Q10 with a known antiinflammatory and antioxidant has beneficial effects on endothelial function and therefore minimize the microvascular and macrovascular complication in patients with type 1 diabetes mellitus.
Administration of Co Q10 for 3 months in type 1 diabetes mellitus in pediatric patients was will tolerated but had no favorable effect on endothelial dysfunction or metabolic parameters .
Co Q10 in addition to improving the metabolic hyperglycemia , it improve Hb A1c and the lipid profile.
patients with type 1 diabetes , especially poorly controlled had elevation of plasma vitamin E and coenzyme Q10 levels and decreased platelet redox status of coenzyme Q10 which may be an indicator of increased oxidative stress ,so Co Q10 has an antioxidant effects.
Researches on this topic are limited on pediatrics and investigators search for it and will see the result.(clinical trial)
Co Q10 is present in the forms of soft gel capsules ,oral spray , hard gel capsules and tablets .
Co Q10 approved from age of 2 years old to 18 years old .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Will take Coenzyme Q10 soft gel capsules or tablets in a dose of 100-200mg of natural factors
Drug: Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets
Will not take Coenzyme Q10 soft gel capsules or tablets
Drug: Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets
Group A will take Soft gel capsules or tablets of Coenzyme Q10 in a dose of 100-200mg of natural factors or kirkman but group B will not take Coenzyme Q10 just observe them
Also known as: Natural factors capsules or Kirkman tablets
Assess the effect of Coenzyme Q10 on glycated haemoglobin in type 1 diabetes mellitus
This prospective randomized clinical trial will be conducted on 100 participants . Half of them will not receive treatment but group A will receive 100-200mg of Coenzyme Q10 . the level of glycated hemoglobin, fasting blood glucose will be assessed for both groups at baseline and after 3 months of treatment for ongoing use in diabetic children
Time frame: One year
Control of random blood sugar and glycated haemoglobin in children with type 1 diabetes mellitus .
By ensuring of regular intake of Coenzyme Q10 capsules or tablets then assessment of glycated hemoglobin
Time frame: One year
No study locations are listed for this record.
Plan to share: No
Start is estimated for Oct 2024; primary completion for Oct 2025, 12 months later.
Of 56 non-industry phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 64. This study's planned 12 months is below that.
Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.